Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication safety review Clear all

Conditions: Polypharmacy
Interventions: TEAM Strategy; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Polypharmacy, Care Transitions, Geriatric Syndromes
Interventions: Shed-Meds: A Patient-Centered Deprescribing Intervention; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Relapsed and/or Refractory Multiple Myeloma
Interventions: MT-0169; Drug
Lead sponsor: Molecular Templates, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more

Conditions: Peanut Allergy
Interventions: ASP0892, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more

Conditions: Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions: Sleep Hygiene Education, Expert-Led Sleep Disorders Screening and Treatment, Online Sleep Disorders Screening; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fear of Falling
Interventions: Activity, Balance, Learning, and Exposure, Fall prevention education; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hospitalization
Interventions: Care Transitions Innovation (C-TraIn); Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Treatment-resistant Depression
Interventions: Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more

Conditions: Healthy Volunteers
Interventions: TAK-020, TAK-020 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Advanced Solid Tumor
Interventions: OBI-992; Drug
Lead sponsor: OBI Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Glendale, California • La Jolla, California • Detroit, Michigan + 3 more

Conditions: Age-Related Osteoporosis
Interventions: Teriparatide, Alendronate; Drug
Lead sponsor: Madhumathi Rao; Other
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Anhydramnios, Potter Syndrome, Lung Hypoplasia, Multicystic Dysplastic Kidney, Multicystic Renal Dysplasia, Bilateral, Lower Urinary Tract Obstructive Syndrome, Fetal Renal Anomaly
Interventions: Serial amnioinfusions with isotonic fluid, Spinal needle, Isotonic fluid; Procedure · Device · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 6 more

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more

Conditions: HCV Infection
Interventions: ABT-333, ketoconazole, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Drug Abuse
Interventions: WIDUS computer-delivered, indirect brief intervention, Nutrition time control/placebo intervention; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: ZB716, Palbociclib; Drug
Lead sponsor: EnhancedBio USA Inc.; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: New York, New York • Charlottesville, Virginia

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Selitrectinib (BAY2731954); Drug
Lead sponsor: Bayer; Industry
Eligibility: 1 Month and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more

Conditions: Healthy Volunteers
Interventions: TAK-915; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lysosomal Acid Lipase Deficiency
Interventions: Sebelipase Alfa; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Up to 8 Months
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: PTSD, Obesity
Interventions: HARPP, control arm for HARPP trial; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Soft Tissue Sarcoma
Interventions: [Ac 225]RTX-2358, [Cu64]LNTH-1363S; Drug · Diagnostic Test
Lead sponsor: Ratio Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Interventions: Long Term Safety Monitoring Procedures; Other
Lead sponsor: Sonoma Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 71 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 10
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 5 more

Search by objective public record fields.

Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management

A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy

A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Comprehensive Police Fatigue Management Program

Exposure Therapy for Fear of Falling in Older Adults

Care Transitions Innovation (C-TraIn)

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

Renal Anhydramnios Fetal Therapy

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

Indirect Assessment and Intervention for Perinatal Drug Use

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Actinium Therapy for Late-stage Aggressive Sarcomas

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic